David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Journal of Business Ethics 77 (1):73 - 84 (2008)
This paper examines one nascent entrepreneurial endeavour intended by Canada's Stem Cell Network to catalyze the commercialization of stem cell research: the creation of a company called "Aggregate Therapeutics". We argue that this initiative, in its current configuration, is likely to result in a breach of public trust owing to three inter-related concerns: conflicts of interest; corporate influence on the university research agenda; and the failure to provide some form of direct return for the public's substantial tax dollar investment. These concerns are common to many efforts to commercialize academic science but are rendered particularly acute in this case given the therapeutic promise of stem cell research and the considerable number of resources related to stem cell research in Canada, which Aggregate Therapeutics is expected to pool. We do, however, believe that the company can be altered to guard against a violation of the public's trust, and so we present concrete modifications to its structure, which we contend should be given immediate consideration
|Keywords||biotechnology Canada commercialization governance intellectual property patent public trust stem cell|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
Baruch Brody (1996). Public Goods and Fair Prices: Balancing Technological Innovation with Social Well‐Being. Hastings Center Report 26 (2):5-11.
Alexander Morgan Capron & Renie Schapiro (2001). Remember Asilomar? Reexamining Science's Ethical and Social Responsibility. Perspectives in Biology and Medicine 44 (2):162-169.
Donald Fisher, Janet Atkinson-Grosjean & Dawn House (2001). Changes in Academy/Industry/State Relations in Canada: The Creation and Development of the Networks of Centres of Excellence. [REVIEW] Minerva 39 (3):299-325.
Maxine Singer (2001). Commentary: What Did the Asilomar Exercise Accomplish, What Did It Leave Undone? Perspectives in Biology and Medicine 44 (2):186-191.
Citations of this work BETA
Françoise Baylis & Matthew Herder (2009). Policy Design for Human Embryo Research in Canada: An Analysis (Part 2 of 2). [REVIEW] Journal of Bioethical Inquiry 6 (3):351-365.
Similar books and articles
Glenn McGee & Arthur L. Caplan (1999). The Ethics and Politics of Small Sacrifices in Stem Cell Research. Kennedy Institute of Ethics Journal 9 (2):151-158.
Melinda B. Fagan (2011). Social Experiments in Stem Cell Biology. Perspectives on Science 19 (3):235-262.
William M. Sage (2010). Will Embryonic Stem Cells Change Health Policy? Journal of Law, Medicine and Ethics 38 (2):342-351.
Timothy Caulfield (2010). Stem Cell Research and Economic Promises. Journal of Law, Medicine and Ethics 38 (2):303-313.
David Magnus (2010). Translating Stem Cell Research: Challenges at the Research Frontier. Journal of Law, Medicine and Ethics 38 (2):267-276.
Shawn H. E. Harmon (2008). Emerging Technologies and Developing Countries: Stem Cell Research Regulation and Argentina. Developing World Bioethics 8 (2):138-150.
Ronald K. F. Fung & Ian H. Kerridge (2013). Uncertain Translation, Uncertain Benefit and Uncertain Risk: Ethical Challenges Facing First-in-Human Trials of Induced Pluripotent Stem (Ips) Cells. Bioethics 27 (2):89-96.
Mark T. Brown (2009). Moral Complicity in Induced Pluripotent Stem Cell Research. Kennedy Institute of Ethics Journal 19 (1):pp. 1-22.
Nikolaus Knoepffler (2004). Stem Cell Research: An Ethical Evaluation of Policy Options. Kennedy Institute of Ethics Journal 14 (1):55-74.
Added to index2009-01-28
Total downloads7 ( #188,122 of 1,102,759 )
Recent downloads (6 months)1 ( #296,987 of 1,102,759 )
How can I increase my downloads?